EVAX - Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01 | Benzinga
- Initial EVX-01 Phase 2 data confirms the strong Phase 1 results
- After undergoing EVX-01 treatment, a significant and continuous tumor reduction was observed in a metastatic melanoma patient with initial progressive disease
COPENHAGEN, Denmark, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in the development of AI-Immunology™ powered vaccines, is pleased to announce initial results from the EVX-01 Phase 2 clinical trial, confirming previous successful Phase 1 findings. A comprehensive clinical update will be presented at the Society for Immunotherapy of Cancer (SITC) 38th annual meeting, taking place in San Diego, California, from November 1-5, 2023.
Key highlights of the initial Phase 2 results for the first five metastatic melanoma patients treated with EVX-01 include:
- Phase 2 data confirm the favorable safety profile of EVX-01 observed in the Phase 1 trial
- Promising immunological and clinical outcomes align with the Phase 1 outcomes
- Upon EVX-01 treatment, a pronounced and ongoing tumor reduction was observed in a patient with progressive disease
- Phase 2 data confirms Evaxion's AI-Immunology™ platform's ability to identify therapeutically relevant cancer vaccine targets
Christian Kanstrup, CEO of Evaxion, stated, "We firmly believe that our AI-Immunology™ platform has the potential to revolutionize the field of oncology and infectious diseases. Today's update underscores its promise in immuno-oncology, with our EVX-01 vaccine safely eliciting robust immune responses in all patients. Notably, a pronounced tumor reduction in a metastatic patient with initial progressive disease following EVX-01 treatment offers hope for those with life-threatening cancer. We are looking forward to discussing these results with potential partners."
Join us at ...